Rakesh Dattani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rakesh Dattani has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Frederick Wai Keung Tam
Immunology and Inflammation, Imperial College London, London, UK
3 shared publications Zia Ul-Haq
Imperial College Healthcare Partners , London
3 shared publicationsAndrew H Frankel
Imperial College Healthcare NHS Trust , London
2 shared publicationsAra Darzi
Institute of Global Health Innovation, Imperial College London, London, UK
2 shared publicationsFrederick W K Tam
Imperial College Healthcare NHS Trust , London
2 shared publicationsGulam Muktadir
Imperial College Healthcare Partners , London
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Low Rates of Kidney Disease testing and Chronic Kidney Disease coding in At-Risk Adults: An 11-Year Population-Based Study in North West London
Background: Chronic kidney disease (CKD) is a major public health challenge. Early detection in individuals at increased risk may enable timely intervention, yet adherence to recommended screening in routine clinical practice remains uncertain. We evaluated CKD testing and coding practices over an 11-year period in North West London (NWL). Methods: We conducted a retrospective population-based cohort study using the Discover-NOW dataset, comprising de-identified electronic health records for over 2.8 million individuals in NWL. Adults aged ≥18 years without a prior diagnosis of CKD but with at least one clinical risk factor as of 1 January 2010 were included and followed until 31 December 2021. Kidney testing activity was assessed using recorded estimated glomerular filtration rate (eGFR) and/or urine albumin-to-creatinine ratio (uACR) measurements among individuals at increased risk of CKD. As the clinical indication for testing was unavailable, it was not possible to determine whether these investigations were performed specifically for CKD screening or for other clinical indications. Results: Of 1,055,325 adults without CKD at baseline, 279,079 (26.4%) had at least one clinical risk factor and were included. Across the study period, a mean of 60.3% of at-risk individuals did not undergo any CKD testing in a given year. Annual eGFR testing was recorded in 38.7%, while uACR testing was markedly lower at 5.8%. Between 2010 and 2021, 14,874 individuals received a coded diagnosis of CKD. In the absence of confirmation of chronicity, up to 22,581 individuals had laboratory abnormalities potentially compatible with CKD without a corresponding diagnostic code. Conclusions: Kidney testing and CKD coding among at risk adults in NWL were suboptimal during the study period, particularly for albuminuria testing. These findings demonstrate a gap between guideline recommendations and recorded practice. Further evaluation is required to determine whether these patterns have changed following recent advances in CKD treatment and awareness.
- 10 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Open AccessLow Rates of Kidney Disease testing and Chronic Kidney Disease coding in At-Risk Adults: An 11-Year Population-Based Study in North West London
Background: Chronic kidney disease (CKD) is a major public health challenge. Early detection in individuals at increased risk may enable timely intervention, yet adherence to recommended screening in routine clinical practice remains uncertain. We evaluated CKD testing and coding practices over an 11-year period in North West London (NWL). Methods: We conducted a retrospective population-based cohort study using the Discover-NOW dataset, comprising de-identified electronic health records for over 2.8 million individuals in NWL. Adults aged ≥18 years without a prior diagnosis of CKD but with at least one clinical risk factor as of 1 January 2010 were included and followed until 31 December 2021. Kidney testing activity was assessed using recorded estimated glomerular filtration rate (eGFR) and/or urine albumin-to-creatinine ratio (uACR) measurements among individuals at increased risk of CKD. As the clinical indication for testing was unavailable, it was not possible to determine whether these investigations were performed specifically for CKD screening or for other clinical indications. Results: Of 1,055,325 adults without CKD at baseline, 279,079 (26.4%) had at least one clinical risk factor and were included. Across the study period, a mean of 60.3% of at-risk individuals did not undergo any CKD testing in a given year. Annual eGFR testing was recorded in 38.7%, while uACR testing was markedly lower at 5.8%. Between 2010 and 2021, 14,874 individuals received a coded diagnosis of CKD. In the absence of confirmation of chronicity, up to 22,581 individuals had laboratory abnormalities potentially compatible with CKD without a corresponding diagnostic code. Conclusions: Kidney testing and CKD coding among at risk adults in NWL were suboptimal during the study period, particularly for albuminuria testing. These findings demonstrate a gap between guideline recommendations and recorded practice. Further evaluation is required to determine whether these patterns have changed following recent advances in CKD treatment and awareness.
- Open Access
- 26 October 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (4) , e003029
Under-recognition of metabolic syndrome in North West London (2000–2023): a 23-year retrospective analysis
- 26 October 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (4) , e003029
Open AccessUnder-recognition of metabolic syndrome in North West London (2000–2023): a 23-year retrospective analysis
- Open Access
- 29 May 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
A real-world preventive primary care model for cardiorenal metabolic disease: clinical impact of a personalised care approach in Harrow, North West London
Background: Cardiorenal metabolic (CRM) disease, is identified by the co-location of multiple disorders including obesity, diabetes, hypertension, cardiovascular disease and chronic kidney disease (CKD). Early intervention is essential to slow CKD progression, reduce cardiovascular risk, and improve quality of life. The Harrow CRM Hub project established a personalised, multidisciplinary pathway to identify high-risk patients, optimise clinical management, and provide access to lifestyle and psychosocial support. This paper reports on the clinical outcomes achieved within the first year of implementation. Methods: A comprehensive logic model was co-developed to guide the design, delivery, and evaluation of the Harrow CRM programme. Two EHR-identified cohorts were invited: (1) adults aged 20–80 years with BMI >27.5–30 kg/m² (ethnicity-dependent) and non-diabetic hyperglycaemia ± hypertension (CRM Stage 2); and (2) adults with diabetes ± CKD or CVD (CRM Stage 4). Pre visit health questionnaire – using digital tools enabled detailed pre visit updates and tests. Protected consultations (lasting 30 to 45 minutes) followed a structured EHR template incorporating guideline-based optimisation of pharmacotherapy, risk calculators, and co-created lifestyle care plans. Data were extracted for paired analysis of systolic BP, HbA1c, and weight. A qualitative evaluation was undertaken to explore patient and staff experiences of the CRM pathway. Results: Thus far, between November 2024 and September 2025, 2,641 patients were reviewed, with 2,300 included in paired analysis. Across the full cohort, mean changes were −3.65 mmHg in systolic BP (median −2.0 mmHg), −1.03 mmol/mol in HbA1c (median 0.0 mmol/mol), and −0.46 kg in weight (median 0.0 kg) (all p<0.001). For those with an improvement only - an average improvement of −14.12 mmHg (n=1,279) and an average deterioration of +10.61 mmHg among those whose readings worsened (n=895). HbA1c values showed a mean cohort wide reduction of −1.03 mmol/mol (median 0.0 mmol/mol), with mean changes of −8.08 mmol/mol among improvers (n=785) and +5.22 mmol/mol among those with deterioration (n=762). Weight trends showed a mean overall reduction of −0.46 kg (median 0.0 kg), comprising an average improvement of −3.63 kg among improvers (n=1,124) and deterioration of +3.93 kg among those with deterioration (n=761). Among those with paired readings, 33.4% achieved ≥5% BP reduction and 19.7% achieved ≥10%; 19.8% achieved ≥5% HbA1c improvement and 12.7% ≥10%; and 9.6% achieved ≥5% weight loss and 2.7% ≥10%. Overall, 73.9% improved in ≥1 parameter, while 10.4% improved across BP, HbA1c, and weight simultaneously. This real world review identified patients with improvements and deterioration in their health parameters. Qualitative findings showed patients valued extended consultations and holistic discussions, with vast majority of patients reporting greater understanding of their health and feeling more confident to manage it. A staff survey (n=14) provided supportive but preliminary quantitative evidence of having greater confidence in delivering CRM clinics and increased ability to access multidisciplinary expertise. Conclusion: A personalised, multidisciplinary CRM model embedded within primary care was associated with statistically and clinically significant improvements in blood pressure, glycaemic control, and weight in a large, ethnically diverse population. Patients and clinicians both reported greater engagement, confidence, and satisfaction. The approach combining structured identification, extended consultations, co-produced care plans, and workforce education demonstrates a scalable, sustainable pathway to slow CKD progression, reduce CVD risk, and enhance patient wellbeing across diverse communities.
- 29 May 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessA real-world preventive primary care model for cardiorenal metabolic disease: clinical impact of a personalised care approach in Harrow, North West London
Background: Cardiorenal metabolic (CRM) disease, is identified by the co-location of multiple disorders including obesity, diabetes, hypertension, cardiovascular disease and chronic kidney disease (CKD). Early intervention is essential to slow CKD progression, reduce cardiovascular risk, and improve quality of life. The Harrow CRM Hub project established a personalised, multidisciplinary pathway to identify high-risk patients, optimise clinical management, and provide access to lifestyle and psychosocial support. This paper reports on the clinical outcomes achieved within the first year of implementation. Methods: A comprehensive logic model was co-developed to guide the design, delivery, and evaluation of the Harrow CRM programme. Two EHR-identified cohorts were invited: (1) adults aged 20–80 years with BMI >27.5–30 kg/m² (ethnicity-dependent) and non-diabetic hyperglycaemia ± hypertension (CRM Stage 2); and (2) adults with diabetes ± CKD or CVD (CRM Stage 4). Pre visit health questionnaire – using digital tools enabled detailed pre visit updates and tests. Protected consultations (lasting 30 to 45 minutes) followed a structured EHR template incorporating guideline-based optimisation of pharmacotherapy, risk calculators, and co-created lifestyle care plans. Data were extracted for paired analysis of systolic BP, HbA1c, and weight. A qualitative evaluation was undertaken to explore patient and staff experiences of the CRM pathway. Results: Thus far, between November 2024 and September 2025, 2,641 patients were reviewed, with 2,300 included in paired analysis. Across the full cohort, mean changes were −3.65 mmHg in systolic BP (median −2.0 mmHg), −1.03 mmol/mol in HbA1c (median 0.0 mmol/mol), and −0.46 kg in weight (median 0.0 kg) (all p<0.001). For those with an improvement only - an average improvement of −14.12 mmHg (n=1,279) and an average deterioration of +10.61 mmHg among those whose readings worsened (n=895). HbA1c values showed a mean cohort wide reduction of −1.03 mmol/mol (median 0.0 mmol/mol), with mean changes of −8.08 mmol/mol among improvers (n=785) and +5.22 mmol/mol among those with deterioration (n=762). Weight trends showed a mean overall reduction of −0.46 kg (median 0.0 kg), comprising an average improvement of −3.63 kg among improvers (n=1,124) and deterioration of +3.93 kg among those with deterioration (n=761). Among those with paired readings, 33.4% achieved ≥5% BP reduction and 19.7% achieved ≥10%; 19.8% achieved ≥5% HbA1c improvement and 12.7% ≥10%; and 9.6% achieved ≥5% weight loss and 2.7% ≥10%. Overall, 73.9% improved in ≥1 parameter, while 10.4% improved across BP, HbA1c, and weight simultaneously. This real world review identified patients with improvements and deterioration in their health parameters. Qualitative findings showed patients valued extended consultations and holistic discussions, with vast majority of patients reporting greater understanding of their health and feeling more confident to manage it. A staff survey (n=14) provided supportive but preliminary quantitative evidence of having greater confidence in delivering CRM clinics and increased ability to access multidisciplinary expertise. Conclusion: A personalised, multidisciplinary CRM model embedded within primary care was associated with statistically and clinically significant improvements in blood pressure, glycaemic control, and weight in a large, ethnically diverse population. Patients and clinicians both reported greater engagement, confidence, and satisfaction. The approach combining structured identification, extended consultations, co-produced care plans, and workforce education demonstrates a scalable, sustainable pathway to slow CKD progression, reduce CVD risk, and enhance patient wellbeing across diverse communities.
- Open Access
- 1 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (5)
Barriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England
- 1 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (5)
Open AccessBarriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England
- Open Access
- 8 August 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (4) , e003873
Real-world study of the multimorbidity and health service utilisation among individuals with non-diabetic hyperglycemia and type 2 diabetes mellitus in North West London
Introduction The prevalence of non-diabetic hyperglycemia (NDH) and type 2 diabetes mellitus (T2DM) is increasing. While T2DM is recognised to be associated with multimorbidity and early mortality, people with NDH are frequently thought to be devoid of such complications, potentially exposing individuals with NDH to suboptimal care. We therefore used the Discover London Secure Data Environment (SDE) dataset to appreciate the relationship of NDH/T2DM with multimorbidity, healthcare usage, and clinical outcomes. Research design and methods The dataset was retrospectively analysed between January 1, 2015 and December 31, 2020 to understand the relationship between NDH/T2DM and multimorbidity primary/secondary healthcare usage and clinical outcomes. This was compared with a cohort of individuals with thyroid disease but no NDH/T2DM. Results The dataset identified 152,384 and 124,190 adults with NDH and T2DM compared with 11,626 individuals with thyroid disease (control group). Individuals with NDH and individuals with T2DM had a high burden of disease, with only 13.1% of individuals with either NDH or T2DM not found to be suffering from at least one of the disease states of interest. The three most common comorbidities experienced by individuals with NDH were hypertension (41.4%), hypercholesterolemia (37.5%), and obesity (29.8%) compared with retinopathy (68.7%), hypertension (59.4%), and obesity (45.8%) in individuals with T2DM. Comparatively, the most common comorbidities in the control group were depression (30.8%), hypercholesterolemia (24.4%), and hypertension (17.1%). 28 (control group), 12 (NDH), and 16 (T2DM) primary care contacts per individual per year were identified, with 27,881, 282,371, and 314,880 inpatient admissions for the control, NDH, and T2DM cohorts, respectively. Prescription of drugs used to treat T2DM in individuals with NDH and T2DM was 27,772 (18.2%) and 109,361 (88.1%), respectively, accounting for approximately one in five individuals with NDH developing T2DM. Conclusion Both NDH and T2DM were associated with significant multimorbidity alongside primary and secondary care utilisation. Given the morbidity highlighted with NDH, we highlight the need for earlier detection of NDH, recognition of multimorbidity associated with both NDH and T2DM, as well as the need for the further implementation of interventions to prevent progression to T2DM/multimorbidity.
- 8 August 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (4) , e003873
Open AccessReal-world study of the multimorbidity and health service utilisation among individuals with non-diabetic hyperglycemia and type 2 diabetes mellitus in North West London
Introduction The prevalence of non-diabetic hyperglycemia (NDH) and type 2 diabetes mellitus (T2DM) is increasing. While T2DM is recognised to be associated with multimorbidity and early mortality, people with NDH are frequently thought to be devoid of such complications, potentially exposing individuals with NDH to suboptimal care. We therefore used the Discover London Secure Data Environment (SDE) dataset to appreciate the relationship of NDH/T2DM with multimorbidity, healthcare usage, and clinical outcomes. Research design and methods The dataset was retrospectively analysed between January 1, 2015 and December 31, 2020 to understand the relationship between NDH/T2DM and multimorbidity primary/secondary healthcare usage and clinical outcomes. This was compared with a cohort of individuals with thyroid disease but no NDH/T2DM. Results The dataset identified 152,384 and 124,190 adults with NDH and T2DM compared with 11,626 individuals with thyroid disease (control group). Individuals with NDH and individuals with T2DM had a high burden of disease, with only 13.1% of individuals with either NDH or T2DM not found to be suffering from at least one of the disease states of interest. The three most common comorbidities experienced by individuals with NDH were hypertension (41.4%), hypercholesterolemia (37.5%), and obesity (29.8%) compared with retinopathy (68.7%), hypertension (59.4%), and obesity (45.8%) in individuals with T2DM. Comparatively, the most common comorbidities in the control group were depression (30.8%), hypercholesterolemia (24.4%), and hypertension (17.1%). 28 (control group), 12 (NDH), and 16 (T2DM) primary care contacts per individual per year were identified, with 27,881, 282,371, and 314,880 inpatient admissions for the control, NDH, and T2DM cohorts, respectively. Prescription of drugs used to treat T2DM in individuals with NDH and T2DM was 27,772 (18.2%) and 109,361 (88.1%), respectively, accounting for approximately one in five individuals with NDH developing T2DM. Conclusion Both NDH and T2DM were associated with significant multimorbidity alongside primary and secondary care utilisation. Given the morbidity highlighted with NDH, we highlight the need for earlier detection of NDH, recognition of multimorbidity associated with both NDH and T2DM, as well as the need for the further implementation of interventions to prevent progression to T2DM/multimorbidity.
- Open Access
- 25 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0289838
Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study
Introduction: The prevalence of Diabetic Kidney Disease (DKD) secondary to Type 2 Diabetes Mellitus (T2DM) is rising worldwide. However, real-world data linking glomerular function and albuminuria to the degree of multi-morbidity is lacking. We thus utilised the Discover dataset, to determine this association. Method: Patients with T2DM diagnosed prior to 1st January 2015 with no available biochemical evidence of CKD were included. Patients subsequently diagnosed and coded for CKD3a in 2015, were grouped by the degree of albuminuria. Baseline and 5-year co-morbidity was determined, as were prescribing practices with regards to prognostically beneficial medication. Results: We identified 56,261 patients with T2DM, of which 1082 had CKD stage 3a diagnosed in 2015 (224-CKD3aA1,154-CKD3aA2,93-CKD3aA1; 611 patients with CKD3a but no uACR available in 2015 were excluded from follow up). No statistically significant difference was observed in the degree of co-morbidities at baseline. A significant difference in the degree of hypertension, retinopathy, ischaemic heart disease and vascular disease from baseline compared to study end point was observed for all 3 study groups. Comparing co-morbidities developed at study end point, highlighted a statistical difference between CKD3aA1 Vs CKD3aA3 for retinopathy alone and for hypertension and heart failure between CKD3aA2 Vs CKD3aA3. 40.8% of patients with CKD3aA2 or A3 were prescribed Renin Angiotensin Aldosterone inhibitors (RAASi) therapy between June-December 2021. Survival analysis showed 15% of patients with CKD3aA3 developed CKD stage 5 within 5 years of diagnosis. Discussion: CKD3a secondary to DKD is associated with significant multimorbidity at baseline and 5 years post diagnosis, with CKD3aA3 most strongly associated with CKD progression to CKD 5, heart failure, hypertension and retinopathy compared to CKD3aA1 or CKD3aA2 at 5 years post diagnosis. The lack of uACR testing upon diagnosis and poor prescribing of RAASi, in those with CKD3aA2/A3, raises significant cause for concern. Conclusion: DKD is associated with significant multimorbidity. Significant work is needed to be done to ensure patients undergo testing for uACR, to allow for future risk stratification and ability to be started on prognostically beneficial medication.
- 25 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0289838
Open AccessAssociation and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study
Introduction: The prevalence of Diabetic Kidney Disease (DKD) secondary to Type 2 Diabetes Mellitus (T2DM) is rising worldwide. However, real-world data linking glomerular function and albuminuria to the degree of multi-morbidity is lacking. We thus utilised the Discover dataset, to determine this association. Method: Patients with T2DM diagnosed prior to 1st January 2015 with no available biochemical evidence of CKD were included. Patients subsequently diagnosed and coded for CKD3a in 2015, were grouped by the degree of albuminuria. Baseline and 5-year co-morbidity was determined, as were prescribing practices with regards to prognostically beneficial medication. Results: We identified 56,261 patients with T2DM, of which 1082 had CKD stage 3a diagnosed in 2015 (224-CKD3aA1,154-CKD3aA2,93-CKD3aA1; 611 patients with CKD3a but no uACR available in 2015 were excluded from follow up). No statistically significant difference was observed in the degree of co-morbidities at baseline. A significant difference in the degree of hypertension, retinopathy, ischaemic heart disease and vascular disease from baseline compared to study end point was observed for all 3 study groups. Comparing co-morbidities developed at study end point, highlighted a statistical difference between CKD3aA1 Vs CKD3aA3 for retinopathy alone and for hypertension and heart failure between CKD3aA2 Vs CKD3aA3. 40.8% of patients with CKD3aA2 or A3 were prescribed Renin Angiotensin Aldosterone inhibitors (RAASi) therapy between June-December 2021. Survival analysis showed 15% of patients with CKD3aA3 developed CKD stage 5 within 5 years of diagnosis. Discussion: CKD3a secondary to DKD is associated with significant multimorbidity at baseline and 5 years post diagnosis, with CKD3aA3 most strongly associated with CKD progression to CKD 5, heart failure, hypertension and retinopathy compared to CKD3aA1 or CKD3aA2 at 5 years post diagnosis. The lack of uACR testing upon diagnosis and poor prescribing of RAASi, in those with CKD3aA2/A3, raises significant cause for concern. Conclusion: DKD is associated with significant multimorbidity. Significant work is needed to be done to ensure patients undergo testing for uACR, to allow for future risk stratification and ability to be started on prognostically beneficial medication.
- 30 December 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (3) , 148-154
An international patient-centred study of retroperitoneal fibrosis
Summary: Background: The impact that rare chronic disorders, such as retroperitoneal fibrosis (RPF), can have on the physical and psychological aspects of a patient’s health is poorly understood. Patient-related outcome measures and experiences provide a unique opportunity to understand the impact rare chronic disorders have on a patient’s life as well as allowing healthcare providers to compare and improve performance. Aim: To understand the physical and psychosocial impact that RPF has upon peoples’ lives. Design: An international online questionnaire was therefore created to gain insights into how patients with RPF, a rare fibro-inflammatory condition, viewed their health and experiences. Methods: An international online questionnaire comprising 62 questions/free text options, was designed in collaboration with two patient advocates and the multi-disciplinary Renal Association Rare Disease Registry (RaDaR) RPF Group the questionnaire was anonymous and freely accessible on a GOOGLE Form online platform for 6 months. Results: A total of 229 patients from 30 countries across 5 continents responded. Four key issues were identified; (i) pain; (ii) therapy-related side effects; (iii) lack of informed doctors/information about their condition and its management; and (iv) psychological burden. Variations in diagnosis and management are highlighted with 55% undergoing a biopsy to reach a diagnosis of RPF; 75% of patients underwent a further interventional procedure with 60% concurrently treated medically. Conclusion: This study will guide further development of clinical and academic multi-disciplinary activity and shows the importance of trying to understand the impact of rare chronic disorders on the physical and psychological aspects of a patient’s health.
- 30 December 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (3) , 148-154
An international patient-centred study of retroperitoneal fibrosis
Summary: Background: The impact that rare chronic disorders, such as retroperitoneal fibrosis (RPF), can have on the physical and psychological aspects of a patient’s health is poorly understood. Patient-related outcome measures and experiences provide a unique opportunity to understand the impact rare chronic disorders have on a patient’s life as well as allowing healthcare providers to compare and improve performance. Aim: To understand the physical and psychosocial impact that RPF has upon peoples’ lives. Design: An international online questionnaire was therefore created to gain insights into how patients with RPF, a rare fibro-inflammatory condition, viewed their health and experiences. Methods: An international online questionnaire comprising 62 questions/free text options, was designed in collaboration with two patient advocates and the multi-disciplinary Renal Association Rare Disease Registry (RaDaR) RPF Group the questionnaire was anonymous and freely accessible on a GOOGLE Form online platform for 6 months. Results: A total of 229 patients from 30 countries across 5 continents responded. Four key issues were identified; (i) pain; (ii) therapy-related side effects; (iii) lack of informed doctors/information about their condition and its management; and (iv) psychological burden. Variations in diagnosis and management are highlighted with 55% undergoing a biopsy to reach a diagnosis of RPF; 75% of patients underwent a further interventional procedure with 60% concurrently treated medically. Conclusion: This study will guide further development of clinical and academic multi-disciplinary activity and shows the importance of trying to understand the impact of rare chronic disorders on the physical and psychological aspects of a patient’s health.
- 11 December 2020
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 51 (11) , 903-906
The Effect of Kidney Biopsy on Glomerular Filtration Rate: A Frequent Patient Concern
The effect of percutaneous kidney biopsy on glomerular filtration rate has never been identified, though it is frequently a concern raised by patients. Following a clinical interaction with an inquisitive patient undergoing her fifth biopsy, we attempted to estimate the effect using retrospective data. In a cohort of patients with stable kidney function undergoing transplant biopsy without clinical indication (as part of a surveillance programme) the effect of biopsy was observed as a step change in glomerular filtration rate. Reassuringly, the loss of glomerular filtration rate resulting from a biopsy, has a 1-sided 95% confidence interval of <1.4 mL/min.
- 11 December 2020
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 51 (11) , 903-906
The Effect of Kidney Biopsy on Glomerular Filtration Rate: A Frequent Patient Concern
The effect of percutaneous kidney biopsy on glomerular filtration rate has never been identified, though it is frequently a concern raised by patients. Following a clinical interaction with an inquisitive patient undergoing her fifth biopsy, we attempted to estimate the effect using retrospective data. In a cohort of patients with stable kidney function undergoing transplant biopsy without clinical indication (as part of a surveillance programme) the effect of biopsy was observed as a step change in glomerular filtration rate. Reassuringly, the loss of glomerular filtration rate resulting from a biopsy, has a 1-sided 95% confidence interval of <1.4 mL/min.
- 1 August 2020
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (8) , 1446-1448
Oral potassium binders: increasing flexibility in times of crisis
Successful and safe management of hyperkalaemia became more pertinent during the coronavirus disease 2019 (COVID-19) pandemic, as nephrologists grappled with delayed transfer of patients into renal centres, difficulties providing short-term haemofiltration in intensive care units (ICUs), minimizing hospital visits and reorganizing haemodialysis (HD) services to facilitate isolated COVID-19 areas. With an unprecedented demand, the need to preserve ICU beds, and an often-reduced work force, changes in medical practice were required.
- 1 August 2020
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (8) , 1446-1448
Oral potassium binders: increasing flexibility in times of crisis
Successful and safe management of hyperkalaemia became more pertinent during the coronavirus disease 2019 (COVID-19) pandemic, as nephrologists grappled with delayed transfer of patients into renal centres, difficulties providing short-term haemofiltration in intensive care units (ICUs), minimizing hospital visits and reorganizing haemodialysis (HD) services to facilitate isolated COVID-19 areas. With an unprecedented demand, the need to preserve ICU beds, and an often-reduced work force, changes in medical practice were required.